Question

A patient is taking methotrexate following an allogeneic stem

cell transplant to prevent graft-versus-host disease. What type of
treatment is this approach?
1) Cytogenetic
2) immunosuppressive
3) myel

Answer 1

Methotrexate used after an allogeneic stem cell transplant to prevent graft-versus-host disease is an immunosuppressive treatment, designed to prevent donated immune cells from attacking the recipient's tissues.

Step-by-step explanation:

The approach of using methotrexate after an allogeneic stem cell transplant to prevent graft-versus-host disease (GVHD) is classified as immunosuppressive treatment. This method is crucial because following a transplant, the mature T cells in the donor's bone marrow might recognize the recipient's tissues as foreign and attack them, leading to GVHD. Symptoms of GVHD often include a rash and liver and mucosa damage. The immunosuppressive methotrexate helps to prevent the donor immune cells from rejecting the recipient's tissues and causing this disease, thus aiding in the successful acceptance of the transplant.